Zhenyi Medical and Grand Pharmaceutical Announce Strategic Collaboration to Advance Cardiovascular Intervention Sector

Trulive, as an innovative platform enterprise in China focusing on the field of cardiovascular diseases with extremely high mortality and disability rates where the domestic market remains a blank space, has core products that address multiple "bottleneck" issues. Its unique technology has achieved several "firsts in China" and "only in China." The company's continuous innovation in medical solutions for cardiovascular diseases will meet the needs of doctors and patients in China and even globally. The precision interventional diagnosis and treatment sector for cardiovascular and cerebrovascular diseases is one of the core business segments of Grand Pharmaceutical Group Limited. In recent years, through overseas expansion, Grand Pharmaceutical has completed product co-research and development, rights acquisition, and commercialization both domestically and internationally. In the fields of coronary, peripheral, neurological, structural, and heart failure diseases, it continues to expand its business areas and achieve technological breakthroughs. The collaboration between Grand Pharmaceutical and Trulive represents complementary strengths as well as a powerful alliance, which is expected to push China's medical device industry to new heights.

Wen Jing, Chairman of TruliveGrand Pharmaceutical Group Limited's vision of "becoming a medical enterprise respected by doctors and patients and giving back to society" highly aligns with Trulive's concept of "saving billions of lives through innovation." Both parties aim to establish a 'China Standard' for cardiovascular interventional devices, ensuring domestically produced equipment not only replaces imports but also leads the development of next-generation technology.

Tang Weikun, President of Grand Pharmaceutical Group LimitedAlso expressed during the event: "Join hands to lead, perfect and far-reaching. 'Perfect' reflects the depth of cooperation, unafraid of industry impacts; 'far-reaching' demonstrates the determination to join hands. Both parties will jointly set a new benchmark in the industry, using innovation as the sail to embark on a new journey."

Photo: Wen Jing (left), Chairman of Trulive, and Chen Xiaojie (right), Vice President of Grand Pharmaceutical Group Limited, sign the agreement.

Currently, the two parties have reached agency cooperation on multiple products under Trulive, including the DEEPQUAKE™ Peripheral Intravascular Shockwave System and the NeoNova® Mitral Valve Clip and Delivery System, which were approved for marketing by the National Medical Products Administration (NMPA) in November 2024 and February 2025, respectively. Both products are at the leading level of Chinese production, offering new treatment options for many patients in China.

From the market perspective, China's interventional medical market has enormous potential. According to the latest research report by QYResearch, the global market size for peripheral vascular interventional devices reached $9.625 billion in 2023, with China accounting for 9.74%. Meanwhile, the population of patients with moderate to severe mitral regurgitation (MR) in China continues to expand (expected to reach 12.6 million by 2027), but limitations in traditional surgery applicability are creating demand for interventional treatments. The number of transcatheter mitral valve interventions is projected to surge from 300 cases in 2021 to 10,900 cases in 2025 (CAGR 157.1%), with penetration increasing to 0.78%. As domestically produced devices gain accelerated approval and technological iteration progresses, market expansion is anticipated.

From the birth of medical innovation achievements to their application in patients, it is necessary to overcome multiple hurdles such as research and development and transformation, which cannot be achieved without the collaborative efforts of industry, academia, and research. Trulive and Grand Pharmaceutical Group Limited have joined hands, with the mission of promoting medical progress and improving the quality of patients' lives, to jointly contribute to the development of the cardiovascular intervention industry.

-End-